Home - JDNPPA

Master Class: Recognizing and Avoiding Filler Complications

LEVEL UP Period 2 Data: AD Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets

October 28, 2024

Now Available: Johnson & Johnson Debuts Tremfya Clearance Photo Library

October 25, 2024

Are Your AD Patients at Higher Risk for Peripheral Vascular Disease?

October 22, 2024

FDA Approves an Additional Presentation of SELARSDI (Ustekinumab-aekn), Aligning the Label With the Indications Approved for Reference Product, Stelara

October 22, 2024

Advertisement

Advertisement

Latest Issue

Latest Supplement

Advertisement

Digital Edition Archive